Illumina downgraded to Neutral from Outperform at RW Baird

RW Baird downgraded Ilumina as the firm believes that the outlook for the company's partnership with BGI has been clouded, and notes that a potential takeover of Ilumina by Roche (RHHBY) fell through previously. Target $54.

Advertisement